ABSTRACT
Aedes-borne diseases infect millions of people each year. In the last decade several arbovirus outbreaks have been reported in Ethiopia. Arbovirus diagnosis and surveillance is lacking and the true burden is unknown. In this study we conducted a seroprevalence survey using a commercially available test kit that that tests for immunological responses to IgM and IgG for dengue (DENV), Zika (ZIKV), and chikungunya (CHIKV) viruses in Dire Dawa city, eastern Ethiopia. We found a high IgG seroprevalence for DENV (76%), CHIKV (44%), and ZIKV (38%), and <20% IgM seropositivity across all viruses. As a comparison, we conducted serosurveillance in Addis Ababa, the national capital with no reported history of arbovirus outbreaks. The highest seropositivity we found was to IgM for DENGV at approximately 3%. Our results suggest both past and recent widespread exposure to these arboviruses, underscoring the need for improved surveillance and public health interventions in Ethiopia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partially funded through a Council on Research, Computing and Libraries (CORCL) pilot grant to DMP and through NIH grants D43 TW001505 and U19 AI129326 to GY.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained from the Institutional Review Board of College of Health Sciences, Addis Ababa University
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Author email addresses: WH: werissawhaileselassie{at}yahoo.com TSH: temesegen.sisay{at}aau.edu.et AW: Arsea2004{at}hotmail.com SW: saleabera{at}yahoo.com XW: xiaomiw1{at}uci.edu ML: mingchil{at}uci.edu GY: guiyuny{at}hs.uci.edu
This revision corrects Figure 1, which originally only presented predicted age specific seropositivity to IgM but now correctly shows predicted age specific seropositivity to IgG and IgM.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
